Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14945052 | 0.92 | ACACB (0.79) | ACACBACACA | |
| SCHEMBL18909871 | 0.91 | ACACB (0.67) | ACACBACACA | |
| SCHEMBL19348111 | 0.90 | ACACB (0.83) | ACACBACACA | |
| SCHEMBL14945053 | 0.90 | ACACA (0.71) | ACACBACACA | |
| SCHEMBL18909776 | 0.88 | ACACB (0.67) | ACACBACACA | |
| SCHEMBL18909787 | 0.88 | ACACB (0.67) | ACACBACACA | |
| SCHEMBL18909780 | 0.88 | ACACB (0.66) | ACACBACACA | |
| SCHEMBL18909778 | 0.88 | ACACB (0.66) | ACACBACACA | |
| SCHEMBL18910803 | 0.87 | ACACB (0.66) | ACACBACACA | |
| SCHEMBL18910802 | 0.87 | ACACB (0.66) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3380478-B1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091602-A1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.